Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world blood concentration analysis of zanubrutinib in malignant lymphoma
ChiCTR2600125549Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL) and Waldenström macroglobulinemia (WM), sponsored by Shanghai General Hospital. Primary endpoints: progression free survival and objective remission rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on ChiCTR2600125549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125549.